close 74% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

6.07 -1.46

Buy

Prijsupdate 17 sep 2025, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.97

Max

6.23

Belangrijke statistieken

By Trading Economics

Inkomsten

-14M

-37M

Verkoop

7.9M

38M

EPS

-4.07

Winstmarge

-98.215

Werknemers

279

EBITDA

8.9M

-24M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+191.53% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

21M

56M

Vorige openingsprijs

7.53

Vorige sluitingsprijs

6.07

Nieuwssentiment

By Acuity

100%

0%

185 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 sep 2025, 23:01 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

DJ

Lezen

17 sep 2025, 22:48 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

DJ

Lezen

17 sep 2025, 21:59 UTC

Winsten

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

DJ

Lezen

17 sep 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

DJ

Lezen

17 sep 2025, 23:39 UTC

Marktinformatie

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

DJ

Lezen

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

DJ

Lezen

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

DJ

Lezen

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

DJ

Lezen

17 sep 2025, 22:19 UTC

Acquisities, Fusies, Overnames

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

DJ

Lezen

17 sep 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

DJ

Lezen

17 sep 2025, 21:00 UTC

Winsten

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

DJ

Lezen

17 sep 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

17 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

17 sep 2025, 19:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

17 sep 2025, 19:59 UTC

Marktinformatie

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

DJ

Lezen

17 sep 2025, 19:07 UTC

Marktinformatie

Oil Futures Snap Three-Session Winning Streak -- Market Talk

DJ

Lezen

17 sep 2025, 18:43 UTC

Marktinformatie

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

DJ

Lezen

17 sep 2025, 18:38 UTC

Marktinformatie

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

DJ

Lezen

17 sep 2025, 18:20 UTC

Marktinformatie

Gold Dips After Quarter-Point Rate Cut -- Market Talk

DJ

Lezen

17 sep 2025, 18:18 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

17 sep 2025, 18:18 UTC

Marktinformatie

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

DJ

Lezen

17 sep 2025, 18:14 UTC

Marktinformatie

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

DJ

Lezen

17 sep 2025, 17:59 UTC

Marktinformatie

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

DJ

Lezen

17 sep 2025, 17:15 UTC

Acquisities, Fusies, Overnames

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

DJ

Lezen

17 sep 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

DJ

Lezen

17 sep 2025, 16:51 UTC

Winsten

Correct: Exor 1H Net Loss -EUR624M

DJ

Lezen

17 sep 2025, 16:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

17 sep 2025, 16:34 UTC

Marktinformatie

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

DJ

Lezen

17 sep 2025, 16:25 UTC

Winsten

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

DJ

Lezen

17 sep 2025, 16:23 UTC

Winsten

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

191.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.25 USD  191.53%

Hoogste 30 USD

Laagste 8 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

185 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

759.75

↓-0.52%

JNJ

Johnson and Johnson

176.59

↑ +0.08%

ABBV

AbbVie Inc

220.03

↑ +1.83%

UNH

UnitedHealth Group Inc

341.1

↑ +0.38%

AZN

AstraZeneca PLC ADR

77.6

↓-0.01%
help-icon Live chat